Sugi Predict

Sugi Predict / Compounds / SCHEMBL553101

SCHEMBL553101

SCHEMBL553101

COC(=O)c1cc(Br)cc2cc[nH]c12

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 2/20 0.50
▸ NR4A2 P43354 2/20 0.46
▸ PIM3 Q86V86 2/20 0.43
▸ PIM1 P11309 1/20 0.43
▸ MAOB P27338 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ IKBKB O14920 4/20 0.39
▸ CHUK O15111 4/20 0.39
▸ KEAP1 Q14145 1/20 0.39
▸ GAA P10253 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ TTBK1 Q5TCY1 1/20 0.38
▸ TTBK2 Q6IQ55 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ PDPK1 O15530 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL618995 0.84 ALDH1A1 (0.46) MAOBL3MBTL1GAAALDH1A1MAPT
SCHEMBL988102 0.83 NR4A2 (0.44) CHEK1NR4A2PIM3PIM1MAOB
SCHEMBL17802189 0.83 PIM3 (0.44) CHEK1NR4A2PIM3PIM1MAOB
SCHEMBL20542164 0.83 PIM3 (0.44) CHEK1NR4A2PIM3PIM1MAOB
SCHEMBL29696538 0.83 PIM3 (0.44) CHEK1NR4A2PIM3PIM1MAOB
SCHEMBL24597299 0.83 CA12 (0.49) CHEK1NR4A2PIM3PIM1MAOB
SCHEMBL29691389 0.83 CA12 (0.49) CHEK1NR4A2PIM3PIM1MAOB
SCHEMBL10211382 0.82 MAOA (0.43) CHEK1NR4A2MAOBIKBKBCHUK
SCHEMBL20541577 0.81 CHEK1 (0.50) CHEK1NR4A2PIM3PIM1IKBKB
SCHEMBL552639 0.80 KEAP1 (0.56) NR4A2IKBKBCHUKKEAP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179017-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) 2025-06-05 — — US disclosed
CN-119487006-A Amide compounds as PGE2 receptor antagonists 广东新契生物医药科技有限公司 2025-02-18 — — CN disclosed
EP-4482824-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS Guangdong Newopp Biopharmaceuticals Co., Ltd. (CN) 2025-01-01 — — EP disclosed
WO-2023160569-A9 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) 2024-03-07 — — WO disclosed
EP-4271374-A1 SOS1 INHIBITORS AND USES THEREOF Revolution Medicines, Inc. (US) 2023-11-08 — — EP disclosed
CN-116916914-A SOS1 inhibitors and uses thereof 锐新医药公司 2023-10-20 — — CN disclosed
WO-2023160569-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) 2023-08-31 — — WO disclosed
CN-116041344-A Bicyclic heteroaryl carboxamide compounds as SOS1 inhibitors 北京望实智慧科技有限公司 2023-05-02 — — CN disclosed
WO-2022146698-A1 SOS1 INHIBITORS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-07-07 — — WO disclosed
WO-2022146698-A1 SOS1 INHIBITORS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-07-07 — — WO disclosed
WO-2007062318-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-31 — — WO disclosed
EP-1776338-A1 INDOLE, INDAZOLE OR INDOLINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-04-25 — — EP disclosed
CN-1933830-A Indole derivatives and their use as kinase inhibitors, in particular IKK2 inhibitors SMITHKLINE BEECHAM CORP (US) 2007-03-21 — — CN disclosed
WO-2007005534-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-01-11 — — WO disclosed
WO-2007005534-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-01-11 — — WO disclosed
EP-1703905-A1 INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-09-27 — — EP disclosed
WO-2006034317-A2 CHEMICAL COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-03-30 — — WO disclosed
US-20060030613-A1 Indole, indazole and indoline derivatives as CETP inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2006-02-09 — — US disclosed
WO-2006013048-A1 INDOLE, INDAZOLE OR INDOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-02-09 — — WO disclosed
WO-2005067923-A1 INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030613-A1 Indole, indazole and indoline derivatives as CETP inhibitors CETP, NAT1, MTTP CHEK1 2085/4885NR4A2 2861/4885PIM3 988/4885
US-20250179017-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS PTGER1, PTGER2, CNR2 CHEK1 3870/4885NR4A2 942/4885PIM3 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.